• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 3. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 4. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 5. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidine-2-ones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidones Pyrrolidine-2-ones
• Material Chemicals High Polymer Materials Elementary Organic Polymers
• Solvents and Organic Chemicals Organic Compounds Aldehyde/Ketone
• Material Chemicals High Polymer Materials

Polyvinylpyrrolidone (9003-39-8) in Drug Delivery Systems: Enhancing Solubility and Bioavailability

Polyvinylpyrrolidone (PVP), with the CAS number 9003-39-8, is a versatile polymer widely used in the pharmaceutical industry to improve drug delivery systems. Its unique ability to form complexes with poorly water-soluble drugs has made it a cornerstone in enhancing solubility and bioavailability. Recent studies highlight PVP's role in amorphous solid dispersions (ASDs), where it stabilizes active pharmaceutical ingredients (APIs) and prevents crystallization. This is particularly critical for BSC Class II drugs, where solubility limitations hinder therapeutic efficacy. Researchers are also exploring PVP-based nanoparticles and hydrogels for targeted drug release, addressing challenges like gastric degradation and first-pass metabolism. With the rise of personalized medicine, PVP's adaptability in 3D-printed pharmaceuticals further underscores its relevance in modern drug formulation.

Polyvinylpyrrolidone (9003-39-8) as a Stabilizer in Biopharmaceuticals: Protecting Protein Therapeutics

In biopharmaceuticals, 9003-39-8 (PVP) serves as a critical stabilizer for protein-based therapeutics, including monoclonal antibodies and vaccines. Its hydrophilic properties shield proteins from aggregation and denaturation during storage and lyophilization. A 2023 study published in the Journal of Pharmaceutical Sciences demonstrated PVP's efficacy in preserving the conformational integrity of COVID-19 mRNA vaccines under thermal stress. Additionally, PVP's role in lyoprotection (freeze-drying protection) is gaining traction for biologics with short shelf lives. Industry leaders are now optimizing PVP concentrations in biosimilar formulations to match originator products, a key concern for regulatory compliance and cost-effective production. The polymer's low immunogenicity further makes it suitable for parenteral formulations, aligning with the growing demand for injectable biologics.

Safety and Regulatory Status of Polyvinylpyrrolidone (9003-39-8): Compliance in Pharmaceutical Applications

The safety profile of Polyvinylpyrrolidone (9003-39-8) is well-documented, with approvals from the FDA, EMA, and other global agencies for use in oral, topical, and injectable drugs. Its GRAS (Generally Recognized as Safe) status for oral applications and inclusion in the USP-NF monograph ensures broad regulatory acceptance. However, recent debates focus on PVP's molecular weight-dependent renal clearance, prompting studies on high-molecular-weight PVP in chronic formulations. The European Pharmacopoeia's 2024 update specifies stricter limits on residual N-vinylpyrrolidone monomers, driving innovations in purification processes. For consumers, PVP's presence in ophthalmic solutions and wound dressings underscores its biocompatibility, though allergenicity risks in topical products remain under review.

Polyvinylpyrrolidone (9003-39-8) in Novel Medical Devices: From Wound Care to 3D Bioprinting

Beyond traditional pharmaceuticals, 9003-39-8 (PVP) is revolutionizing medical device technology. Its adhesive and film-forming properties are leveraged in transdermal patches for controlled drug release, such as nicotine replacement therapies. In wound care, PVP-iodine complexes (povidone-iodine) dominate as broad-spectrum antimicrobials, with recent advances in nanofibrous wound dressings for diabetic ulcers. The polymer's compatibility with 3D bioprinting has enabled its use in scaffold fabrication for tissue engineering, particularly in cartilage regeneration. A 2023 Nature Materials study highlighted PVP's role in bioinks for printing vascularized tissues, addressing a major hurdle in organ transplantation. As wearable health tech expands, PVP's flexibility in flexible biosensors further positions it at the forefront of medtech innovation.

Future Trends for Polyvinylpyrrolidone (9003-39-8) in Personalized Medicine and Green Chemistry

The future of Polyvinylpyrrolidone (9003-39-8) lies in its integration with personalized medicine and sustainable practices. Researchers are developing PVP-based theranostic systems that combine drug delivery with diagnostic imaging, such as MRI contrast agents. The polymer's tunable solubility supports patient-specific dosing in pediatric and geriatric populations, a priority for regulatory bodies. Concurrently, the push for green chemistry has spurred interest in bio-derived PVP alternatives, though challenges in scalability persist. A 2024 ACS Sustainable Chemistry & Engineering report showcased PVP's recyclability in continuous manufacturing processes, reducing pharmaceutical waste. As AI-driven drug discovery accelerates, PVP's database (e.g., PubChem CID: 6917) is being mined for predictive modeling of polymer-drug interactions, heralding a new era of computational pharmaceutics.

• 2235-00-9(1-ethenylazepan-2-one)
• 26124-23-2(2-Propenamide, polymer with 1-ethenyl-2-pyrrolidinone)
• 26008-54-8(ethenol; 1-ethenylpyrrolidin-2-one)
• 25655-41-8(Povidone iodine)
• 25189-83-7(Luviskol Plus)
• 28158-56-7(Vinylamine-vinylpyrrolidone copolymer)
• 2372-96-5(2,5-Pyrrolidinedione,1-ethenyl-)
• 88-12-0(1-ethenylpyrrolidin-2-one)
• 26660-16-2(1-ETHENYL-1-PYRROLIDINONE, POLYMER WITH ETHENE AND 1-PROPENE)
• 25249-54-1(N-Vinyl-2-pyrrolidone)